DORADO: Opportunity postponed: Lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension

Hypertension

Volumn 56, Issue 5, 2010, Pages 806-807

  Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DARUSENTAN; ENDOTHELIN 1; GUANFACINE; PLACEBO; ENDOTHELIN RECEPTOR; PHENYLPROPIONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; EDEMA; FLUID RETENTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PLACEBO EFFECT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; DRUG ANTAGONISM; TREATMENT OUTCOME;

HUMANS; HYPERTENSION; PHENYLPROPIONATES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 78149237594     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.160952     Document Type: Note

References (9)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment - A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
2. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423-1431.
3. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-830.
4. Pickering TG, Shimbo D, Haas D. Current concepts: ambulatory bloodpressure monitoring. N Engl J Med. 2006;354:2368-2374.
5. Dolan E, O'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010;56:179-181.
6. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008;52:452-459.
7. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V, for the Bosentan Hypertension Investigators. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-790.
8. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R, Rihal C, Lerman LO, Lerman A. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation. 2010;122:958-966.
9. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension. 2009;54:113-119.